Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms

Expert Opinion on Drug Delivery

Volumn 5, Issue 7, 2008, Pages 757-766

  Donnelly, Ryan F ^a   McCarron, Paul A ^a   Morrow, Desmond I J ^a   Sibani, Stéphane A ^a   Woolfson, A David ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

5 aminolevulinic acid; Drug delivery; Photodynamic therapy; Preformed photosensitisers; Topical application

Indexed keywords

6 OXOCHOLESTANOL; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; CETYLPYRIDINIUM SALT; EUDRAGIT; EXCIPAL; GELATIN SPONGE; GLYCEROL OLEATE; HPE 101; LABRAFAC; OLEIC ACID; PHLORETIN; PHOTOFRIN I; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ZINC; POLOXAMER; PORPHIN; PROTOPORPHYRIN; PSORALON; TEMOPORFIN;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BOWEN DISEASE; DRUG DESIGN; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; DRUG TRANSPORT; GEL; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MATERIAL STATE; MOLECULAR WEIGHT; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOSENSITIZATION; PHOTOTOXICITY; RADIATION RESPONSE; REVIEW; SCAR FORMATION; SHELF LIFE; SKIN TUMOR; TRANSDERMAL PATCH; VAGINAL INTRAEPITHELIAL NEOPLASIA;

ADMINISTRATION, TOPICAL; ANIMALS; DRUG CARRIERS; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN ABSORPTION;

EID: 48349148670     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.7.757     Document Type: Review

References (100)

1. Raab O. Uber die wirking fluoreszierender stoffe auf infusorien. Z Biol 1900;39:524-46
2. Von Tappeiner H. Uber die wirkung fluoreszierender stoffe auf infusorien nach versuchen von O.Raab. Muench Med Wochenschr 1900;47:5
3. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem Photobiol 2005;81:750-67
4. De Rosa FS, Bently M. Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives. Pharm Res 2000;17:1447-55
5. Lopez FVR, Lange N, Guy R, Bently M. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev 2004;56:77-94
6. Konan Y, Gurny N, Allemann R. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 2002;66:89-106
7. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin. IX. Basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-8
8. Dougherty TJ. Photoradiation therapy for cutaneous and subcutaneous malignancies. Invest Dermatol 1981;77:122-4
9. Malik Z, Lugaci H. Destruction of erythroleukaemic cells by photoinactivation of endogenous porphyrins. Cancer 1987;56:589-95
10. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001;74:656-69
11. Meijinders PJN, Star WM, De Bruijn RS, et al. Clinical results of photodynamic therapy for superficial skin malignancies or actinic keratosis using topical 5-aminolevulinic acid. Lasers 1996;11:123-31
12. Wyld L, Burn JL, Reed MW, Brown NJ. Factors affecting aminolevulinic acid induced generation of protoporphyrin IX. Cancer 1997;76:705-12
13. Leibovici L, Schoenfeld N, Yehoshua HA, et al. Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer. Cancer 1988;62:2297-300
14. Navone NM, Polo CF, Frisardi AL, et al. Heme biosynthesis in human breast cancer: mimetic in vitro studies and some enzymatic activity levels. Int J Biochem 1990;22:1407-11
15. El-Sharabasy MMH, El-Waseef AM, Hafez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992;65:409-12
16. Dailey HA, Smith A. Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochemistry 1984;223:441-5
17. Cairnduff F, Stringer MR, Hudson EJ, et al. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary cancer. Br J Cancer 1994;69:605-8
18. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical 5-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995;29:53-7
19. Soler AM, Warloe T, Tausjo J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethyl sulfoxide and curettage in nodular basal cell carcinoma: a one year follow up study. Dermatol Venereol 1999;79:204-6
20. Meijnders PJN, Star WM, De Bruijn RS, et al. Clinical results of photodynamic therapy of superficial skin malignancies or actinic keratosis using topical 5-aminolevulinic acid. Lasers 1996;11:123-31
21. Dijkstra AT, Majoie ML, Van Dongen JWF, et al. Photodynamic therapy with violet light and topical 5-aminolevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 2001;15:550-4
22. Jeffes EW, McCullough JL, Weinstein GP, et al. Photodynamnic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose ranging study. Arch Dermatol 1997;133:727-32
23. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical 5-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:743-51
24. Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996;135:766-71
25. Morton CA, Whitehurst C, Moore JV, MacKie RM. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000;143:767-72
26. Fehr MK, Hornung R, Schwarz VA, et al. Photodynamic therapy of vulvar intraeptihelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol Oncol 2001;80:62-6
27. Martin-Hirsch PL, Whitehurst C, Buckley CH, et al. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Arch Dermatol 1998;134:247-9
28. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001;61:192-6
29. Zawislak A, McCarron PA, McCluggage WG, et al. Successful photodynamic therapy of vulval Paget's disease using a novel patch based delivery system containing 5-aminolevulinic acid. Br J Obstet Gynaecol 2004;111:1-3
30. Wierrani F, Kubin A, Jindra R, et al. 5-Aminolevulinic acid mediated photodynamic therapy of intraepithelial neoplasia and human papillomavirus of the uterine cervix - a new experimental approach. Cancer Detect Prev 1999;23:351-5
31. Hurlimann AF, Hanggi G, Panizzon RG. Photodynamic therapy of superficial basal cell carcinoma using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 1998;197:248-54
32. Dougherty TJ, Gormer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905
33. Lieb S, Szeimies RM, Lee G. Self adhesive thin films for topical delivery of 5-aminolevulinic acid. Eur J Pharm Biopharm 2002;53:99-106
34. Casas A, Fukuda G, Di Venosa G, et al. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolevulinic acid: implications in cutaneous photodynamic sensitisation. Br J Dermatol 2000;143:564-72
35. Malik Z, Kostenich G, Roitman L, et al. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J Photochem Photobiol B 1995;28:213-8
36. Morton CA, Whitehurst C, McColl JH, et al. Photodynamic therapy for large or multiple patches of Bowen's sisease and basal cell carcinoma. Arch Dermatol 2001;137:319-24
37. Moan J, Ma LW, Iani V. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int J Cancer 2001;92:139-43
38. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinate-based photodynamic therapy alone with prior curettage. Br J Dermatol 2001;145:467-71
39. Ma L, Moan J, Peng Q, Iani V. Production of protoporphyrin IX induced by 5-aminolevulinic acid in transplanted human colon adenocarcinoma of nude mice can be increased by ultrasound. Int J Cancer 1998;78:464-9
40. Star WM, Aalders MCG, Sac A, Sterenborg HJCM. Quantitative model calculation of the time-dependent protoporphyrin IX concentration in normal human epidermis after delivery of ALA by passive topical application or iontophoresis. Photochem Photobiol 2002;75:429-32
41. Lopez RF, Bentley MV, Delgado-Charro MB, Guy RH. Iontophoretic delivery of 5-aminolevulinic acid: effect of pH. Pharm Res 2001;18:311-5
42. Lee S, Kollias A, McAuliffe DJ, et al. Topical drug delivery in humans with a single photomechanical wave. Pharm Res 1999;16:1717-21
43. Donnelly RF, Morrow DIJ, Garland MJ, et al. Influence of solution viscosity and injection protocol on distribution patterns of jet injectors. Application to photodynamic tumour targeting. J Photochem Photobiol B 2007;89:98-109
44. Donnelly RF, Morrow DIJ, McCarron PA, et al. Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: potential for enhanced topical photodynamic therapy. J Control Release 2008; In press
45. Valenta C, Auner BG, Loibl I. Skin permeation and stability of 5-aminolevulinic acid in a new gel and patch preparation. J Control Release 2005;107:495-501
46. McCarron PA, Donnelly RF, Woolfson AD, Zawislak A. Photodynamic therapy of vulval intraepithelial neoplasia using bioadhesive patch-based delivery of aminolevulinic acid. Drug Del Sys Sci 2003;3:59-64
47. McCarron PA, Donnelly RD, Zawislak A, Woolfon AD. Design and evaluation of a water-soluble bioadhesive patch formulation for cutaneous delivery of 5-aminolevulinic acid to superficial neoplastic lesions. Eur J Pharm Sci 2006;27:268-79
48. Gilmore BF, McCarron PA, Morrow DIJ, et al. In vitro phototoxicity of 5-aminolevulinic acid and its methyl ester and the influence of barrier properties on their release from a bioadhesive patch. Eur J Pharm Biopharm 2006;63:295-309
49. Winkler A, Muller-Goymann CC. Comparative permeation studies for 5-aminolevulinic acid and its n-buryl ester through stratum corneum and artificial skin constructs. Eur J Pharm Biopharm 2002;53:281-7
50. Winkler A, Muller-Goymann CC. The influence of topical formulations on the permeation of 5-aminolevulinic acid and its n-butyl ester through excised human stratum corneum. Eur J Pharm Biopharm 2005;60:427-37
51. McCarron PA, Donnelly RF, Andrews GP, Woolfson AD. Stability of 5-aminolevulinic acid in novel non-aqueous gel and patch-type systems intended for topical application. J Pharm Sci 2005;94:1756-71
52. De Rosa FS, Tedesco AC, Lopez RFV, et al. In vitro permeation and retention of 5-aminolevulinic acid ester derivatives for photodynamic therapy. J Control Release 2003;89:261-9
53. Van den Akker JT, Holroyd JA, Vernon DI, et al. Comparative in vitro percutaneous penetration of 5-aminolevulinic acid and two of its esters through excised hairless mouse skin. Lasers Surg Med 2003;33:173-81
54. Gerscher S, Connelly JP, Griffiths J, et al. Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo. Photochem Photobiol 2000;72:569-74
55. Gerscher S, Connelly JP, Beijersbergen Van Henegouwen GM, et al. A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulunic acid-n-pentlyester. Br J Dermatol 2001;144:983-90
56. Peng Q, Soler AM, Warloe T, et al. Selective distribution of porphyrins in skin-thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001;62:140-5
57. Van den Akker JT, Iani V, Star WM, et al. Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol 2000;72:681-9
58. Peng Q, Moan J, Warloe T, et al. Build-up of esterified aminolevulinic acid derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 1996;34:95-6
59. Moan J, Ma LW, Juzeniene A, et al. Pharmacology of protoporphyrin IX in nude mice after application of ALA and its esters. Int J Cancer 2003;103:132-5
60. Juzeniene A, Juzenas P, Iani V, Moan J. Topical application of 5-aminolevulinic acid and its methylester, hexylester and octylester derivatives: considerations for dosimetry in mouse skin model. Photochem Photobiol 2002;76:329-34
61. Szeimies RM, Karrer S, Radakovic-Fijan A, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-62
62. Yamauchi PS, Lowe NJ, Lask GP, et al. Methyl aminolevulinate and photodynamic therapy in the treatment of actinic keratosis. J Invest Dermatol 2002;119:804
63. Pearse AD. Applications for topical PDT: basal cell carcinomas. Photodyn News 2002;5:1-5
64. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy of non-melanoma skin cancers. Curr Rev Update Mol Immunol 2003;39:1133-6
65. Lange N, Jichlinski P, Zellweger M, et al. Photodetecrion of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporphyrin IX. Br J Cancer 1999;80:185-93
66. De Rosa FS, Marchetti JM, Thomazini JA, et al. A vehicle for photodynamic therapy of skin cancer: influence of dimethyl sulfoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release 2000;65:359-66
67. Steluti R, De Rosa FS, Collett JH, Bentley MVLB. In vitro skin retention and permeation studies for 5-aminolevulinic acid: Effect of a lipid penetration enhancer. Eur J Pharm Sci 2001;13:S132
68. Piere MBP, Ricci E, Tedesco AC, Bentley MV. Olcic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy. Pharm Res 2006;23:360-6
69. Bugaj A, Juzeniene A, Juzenas P, et al. The effect of skin permeation enhancers on the formation of porphyrins in mouse skin during topical application of the methyl ester of 5-aminolevulinic acid. J Photochem Photobiol B 2006;83:94-7
70. Bugaj A, Iani V, Juzeniene A, et al. The effect of dimethyl sulfoxide, 1-[2-(decylthio-)ethyl-]azacyclopentane-2-one and labrafac on porphyrin formation in mouse skin during topical application of methyl 5-aminolevulinate: a fluorescence and extraction study. Photodiagn Photodyn Ther 2006;3:27-33
71. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14
72. Williams AC. Transdermal and topical drug delivery. London, Pharmaceutical Press; 2003
73. Auner BG, Valenta C, Hadgraft J. Influence of lipophilic counter-ions in combination with phloretin and 6-ketocholestanol on the skin permeation of 5-aminolevulinic acid. Int J Pharm 2003;255:109-16
74. Bretschko E, Szeimies RM, Landthaler M, Lee G. Topical 5-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Evaluation of stratum corneum permeability in vitro. J Control Release 1996;42:203-8
75. Pons P, Roald P, Nestor B, et al. Transdermic patches for photodynamic therapy of superficial lesions. Proceedings of the 29th Annual Meeting of the American Society of Photobiology; Chicago, USA; 7 - 12 July 2001 Expert Opiri. Druq Deliv. (2008) 5(7)
76. Valenta C, Auner BG, Loibl I. Skin permeation and stability of 5-aminolevulinic acid in a new gel and patch preparation. J Control Release 2005;107:495-501
77. McCarron PA, Donnelly RF, Gilmore BF, et al. Phototoxicity of 5-aminolevulinic acid in the HeLa cell line as an indicative measure of photodynamic effect after topical administration to gynaecological lesions of intraepithelial form. Pharm Res 2004;21:1873-81
78. McCarron PA, Donnelly RF, Woolfson AD, et al. Photodynamic treatment of lichen sclerosus and squamous hyperplasia using sustained topical delivery of aminolevulinic acid from a novel bioadhesive. Br J Dermatol 2004;151(Suppl 68):105-6
79. McCarron PA, Donnelly RF, Zawislak A, et al. Evaluation of a water-soluble bioadhesive patch for photodynamic therapy of vulval lesions. Int J Pharm 2005;293:11-23
80. Donnelly RF, Ma LW, Juzenas P, et al. Topical bioadhesive patch systems enhance selectivity of protoporphyrin IX accumulation. Photochem Photobiol 2006;82:670-5
81. Donnelly RF, Juzenas P, McCarron PA, et al. Influence of formulation factors on methyl-ALA-induced protoporphyrin IX accumulation in vivo. Photodiag Photodyn Ther 2006;3:190-201
82. Bourre L, Thibaut S, Briffaud A, et al. Potential efficacy of a delta 5-ALA thermosetting gel formulation for use in photodynamic therapy of lesions of the gastrointestinal tract. Pharmacol Res 2002;45:159-65
83. Shah JC, Sadhale Y, Chilukuri-Murthy D. Cubic phase gels as drug delivery systems. Adv Drug Del Revs 2001;47:229-50
84. Bender J, Ericson MB, Merclin N, et al. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J Control Release 2005;106:350-60
85. Turchiello RF, Vena FCB, Maillard PH, et al. Cubic phase gel as drug delivery system for topical application of 5-ALA, its ester derivatives and m-THPC in photodynamic therapy (PDT). J Photochem Photobiol B 2003;70:1-6
86. Wyatt D, Dorschel D. A cubic phase delivery system composed of glycerol monooleate and water for sustained release of water soluble drugs. Pharm Technol 1992;10:116-30
87. Lofroth JE, Andreasson A, Rehmberg G. Liquid crystalline phases as drug delivery systems for drugs. II. In vitro, Proceedings of the 15th International Symposium on Controlled Release of Bioactive Materials; Basel, Switzerland; August 15 - 19 1988. p. 380-1
88. Alfons K, Engstrom S. Drug compatibility with the sponge phases formed in monoolein, water, and propylene glycol or poly(ethylene glycol). J Pharm Sci 1998;87:1527-30
89. 3) phase. Colloids and surf A Physicochem Eng Asp 2003;228:17-24
90. Merclin N, Bender J, Sparr E, et al. Transdermal delivery from a lipid sponge phase - ionotophoretic and passive transport in vitro of 5-aminolevulinic acid and its methyl ester. J Control Release 2004;100:191-8
91. Engstrom S. Drug delivery from cubic and other lipid-water phases. Lipid Technol 1990;2:42-5
92. Bonnett R, Djelal BD, Nguyen A. Physical and chemical studies related to the development of m-THPC (Foscan®) for the photodynamic therapy (PDT) of tumours. J Porph Phthalocyan 2001;5:652-61
93. Gannon MJ, Brown SB. Photodynamic therapy and its applications in gynaecology. Br J Obstet Gynaecol 1999;106:1246-54
94. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci 2007;6:1234-45
95. Ceburkov O, Gollnick H. Photodynamic therapy in dermatology. Eur J Dermatol 2000;10:568-75
96. Karrer S, Abels C, Szeimies RM, et al. Topical application of a first porphycene dye for photodynamic therapy: penetration studies in human perilesional skin and basal cell carcinoma. Arch Dermatol Res 1997;289:132-7
97. Wong TW, Aizawa K, Sheyhedin I, et al. Pilot study of topical delivery of mono-L-aspartyl chiorin e6 (NPe6): implication of topical NPe6-photodynamic therapy. J Pharmacol Sci 2003;93:136-42
98. Boiy A, Roelands R, Roskams T, de Witte PA. Effect of vehicles and esterification on the penetration and distribution of hypericin in the skin of hairless mice. Photodiagn Photodyn Ther 2007;4:130-9
99. Kaestner L, Cesson M, Kassab, et al. Zinc octa-n-alkyl phthalocyanines in photodynamic therapy: photophysical properties, accumulation and apoptosis in cell cultures, studies its erythrocytes and topical application to Balb/c mice skin. Photochem Photobiol Sci 2003;2:660-7
100. Donnelly RF, Morrow DIJ, McCarron PA, et al. Microneedle arrays permit true intradermal delivery of a preformed photosensitiser. Photochem Photobiol 2008; In press